Summary
Bladder Cancer (BC) is the 5th most common cancer in Europe with the incidence of 175.000 cases annually and has the highest lifetime treatment cost of all cancers. At the diagnostic step, a cystoscope is used. Usually, no biopsies are taken as there are no efficient methods to do so in the outpatient care. If the patient has suspected cancer seen on the monitor, they are scheduled for a surgery. At the surgery step, the biopsies are taken and the cancer is removed using a resectoscope. The procedure is difficult to perform. The instrument used is hard (metal, up to 12 mm in diameter) and inflexible (can damage the urethra). There is a high risk of cancer reseeding elsewhere in the bladder. Up to 75 % of BC patients relapse within 5 years. The related costs in the EU are estimated at € 5 billion annually. No development has taken place since the 1960 when the existing instruments were developed.
We have developed and patented the first medical device (called Multi4) which allows for local treatment of BC through flexible cystoscopy during one visit to the urologist. The instrument has 4 functions:
1. Inject local anaesthesia through a thin needle
2. Pieces of the cancer are cut by the specially coated forceps. Bleeding is stopped immediately.
3. The cancer tissue is automatically transported out through the instrument itself.
4. When the forceps are closed, they become a burning electrode used to burn the surface where the cancer was located and ensure that all cancer cells have been killed.
With the Multi4 platform, the patient can have their cancer treated at the first visit to the urologist. The procedure takes 20 minutes. This technology can thus disrupt the existing healthcare pathways where BC is treated through expensive and complicated surgeries.
The proposed project will develop a go-to-market strategy for this ground-breaking deep tech innovation and empower the female founder to scale the company.
We have developed and patented the first medical device (called Multi4) which allows for local treatment of BC through flexible cystoscopy during one visit to the urologist. The instrument has 4 functions:
1. Inject local anaesthesia through a thin needle
2. Pieces of the cancer are cut by the specially coated forceps. Bleeding is stopped immediately.
3. The cancer tissue is automatically transported out through the instrument itself.
4. When the forceps are closed, they become a burning electrode used to burn the surface where the cancer was located and ensure that all cancer cells have been killed.
With the Multi4 platform, the patient can have their cancer treated at the first visit to the urologist. The procedure takes 20 minutes. This technology can thus disrupt the existing healthcare pathways where BC is treated through expensive and complicated surgeries.
The proposed project will develop a go-to-market strategy for this ground-breaking deep tech innovation and empower the female founder to scale the company.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101113295 |
| Start date: | 01-08-2023 |
| End date: | 31-07-2024 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
Bladder Cancer (BC) is the 5th most common cancer in Europe with the incidence of 175.000 cases annually and has the highest lifetime treatment cost of all cancers. At the diagnostic step, a cystoscope is used. Usually, no biopsies are taken as there are no efficient methods to do so in the outpatient care. If the patient has suspected cancer seen on the monitor, they are scheduled for a surgery. At the surgery step, the biopsies are taken and the cancer is removed using a resectoscope. The procedure is difficult to perform. The instrument used is hard (metal, up to 12 mm in diameter) and inflexible (can damage the urethra). There is a high risk of cancer reseeding elsewhere in the bladder. Up to 75 % of BC patients relapse within 5 years. The related costs in the EU are estimated at € 5 billion annually. No development has taken place since the 1960 when the existing instruments were developed.We have developed and patented the first medical device (called Multi4) which allows for local treatment of BC through flexible cystoscopy during one visit to the urologist. The instrument has 4 functions:
1. Inject local anaesthesia through a thin needle
2. Pieces of the cancer are cut by the specially coated forceps. Bleeding is stopped immediately.
3. The cancer tissue is automatically transported out through the instrument itself.
4. When the forceps are closed, they become a burning electrode used to burn the surface where the cancer was located and ensure that all cancer cells have been killed.
With the Multi4 platform, the patient can have their cancer treated at the first visit to the urologist. The procedure takes 20 minutes. This technology can thus disrupt the existing healthcare pathways where BC is treated through expensive and complicated surgeries.
The proposed project will develop a go-to-market strategy for this ground-breaking deep tech innovation and empower the female founder to scale the company.
Status
SIGNEDCall topic
HORIZON-EIE-2022-SCALEUP-02-02Update Date
31-07-2023
Images
No images available.
Geographical location(s)
